文献速递肝胆胰外科

临界可切除与局部晚期胰腺导管腺癌原发化疗的转归

Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · JAMA Surg · 2019-01-01

该前瞻性观察性队列研究在意大利国家胰腺疾病转诊中心纳入680例临界可切除或局部晚期胰腺导管腺癌患者,评估原发化疗的完成率、手术转化率及生存结局;化疗接受率92.9%,完成率71.6%,总切除率15.1%,全队列中位生存12.8个月。

要点

  • 原发化疗接受率92.9%,6个月内完成率71.6%。
  • 总切除率15.1%,临界可切除24.1%,局部晚期9%。
  • 全队列中位生存12.8个月,切除后临界可切除35.4个月、局部晚期41.8个月。

核心结论

  • 该意向性治疗设计的实用观察性队列研究提供了临界可切除和局部晚期胰腺导管腺癌接受当前原发化疗方案的真实世界结局证据。

研究设计与样本

  • 前瞻性观察性队列研究,在意大利国家胰腺疾病转诊中心连续纳入2013年1月至2015年12月诊断的680例临界可切除或局部晚期胰腺导管腺癌患者,随访至2018年6月。

主要发现

  • 680例中临界可切除267例(39.3%),局部晚期413例(60.7%);66例(9.7%)失访。
  • 化疗接受率92.9%(570例),最常用方案为FOLFIRINOX(260例,45.6%)和吉西他滨联合白蛋白结合型紫杉醇(123例,21.6%)。
  • 总切除率15.1%(93/614),其中临界可切除24.1%(60/249),局部晚期9%(33/365),切除与探查比为63.3%。
  • 全队列中位生存12.8个月(95%CI 11.7-13.9);切除患者中,初始临界可切除中位生存35.4个月(95%CI 27.0-43.7),初始局部晚期41.8个月(95%CI 27.5-56.1)。

关键数值与推荐

  • 切除的独立预测因素包括年龄、临界可切除疾病、化疗完成、影像学反应和生化反应。
  • 与生存独立相关的因素包括化疗完成、接受补充放疗和切除。
  • 胰腺切除术后,无治疗前或治疗后因素与生存相关。

临床怎么用

  • 对临界可切除和局部晚期胰腺导管腺癌患者,原发化疗是可行的诱导策略,应关注化疗完成以争取手术转化。
  • 多学科评估后选择化疗方案,化疗后根据影像学和生化反应筛选手术候选者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chemotherapy is the recommended induction strategy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma. However, the associated results on an intention-to-treat basis are poorly understood. OBJECTIVE: To investigate pragmatically the treatment compliance, conversion to surgery, and survival outcomes of patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma undergoing primary chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: This prospective study took place in a national referral center for pancreatic diseases in Italy. Consecutive patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma were enrolled at the time of diagnosis (January 2013 through December 2015) and followed up to June 2018. EXPOSURES: The chemotherapy regimen, assigned based on multidisciplinary evaluation, was delivered either at a hub center or at spoke centers. By convention, primary chemotherapy was considered completed after 6 months. After restaging, surgical candidates were selected based on radiologic and biochemical response. All surgeries were carried out at the hub center. MAIN OUTCOMES AND MEASURES: Rates of receipt and completion of chemotherapy, rates of conversion to surgery, and disease-specific survival. RESULTS: Of 680 patients, 267 (39.3%) had borderline resectable and 413 (60.7%) had locally advanced pancreatic ductal adenocarcinoma. Overall, 66 patients (9.7%) were lost to follow-up. The rate of chemotherapy receipt was 92.9% (n = 570). The chemotherapeutic regimens most commonly used included FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) (260 [45.6%]) and gemcitabine plus nanoparticle albumin-bound-paclitaxel (123 [21.6%]). Nineteen patients (3.3%) receiving chemotherapy died within 6 months, mainly for disease progression. The treatment completion rate was 71.6% (408 of 570). The overall rate of resection was 15.1% (93 of 614) (borderline resectable, 60 of 249 [24.1%]; locally advanced, 33 of 365 [9%]; resection:exploration ratio, 63.3%). Independent predictors of resection were age, borderline resectable disease, chemotherapy completion, radiologic response, and biochemical response. The median survival for the whole cohort was 12.8 (95% CI, 11.7-13.9) months. Factors independently associated with survival were completion of chemotherapy, receipt of complementary radiation therapy, and resection. In patients who underwent resection, the median survival was 35.4 (95% CI, 27.0-43.7) months for initially borderline resectable and 41.8 (95% CI, 27.5-56.1) months for initially locally advanced disease. No pretreatment and posttreatment factors were associated with survival after pancreatectomy. CONCLUSIONS AND RELEVANCE: This pragmatic observational cohort study with an intention-to-treat design provides real-world evidence of outcomes associated with the most current primary chemotherapy regimens used for borderline resectable and locally advanced pancreatic ductal adenocarcinoma.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Maggino L, Malleo G, Marchegiani G, et al. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2019. PMID: 31339530. doi:10.1001/jamasurg.2019.2277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。